

# Minimal reporting standards for pre-clinical research

#### Steven Goodman, MD, PhD

Professor of Medicine and Epidemiology Associate Dean of Clinical & Translational Research Co-director, METRICS (Meta-research Innovation Center at Stanford) Stanford University

Sept 26, 2019





### Concepts poorly taught or understood by junior (and senior?) lab scientists

- Basic elements and formal logic and purpose of experimental design
- Foundations of statistical inference and the meaning of basic statistical summaries.
- How to link Question Design Measurement Conduct Analysis – Inference – Conclusions/Implications – Generalizations.
- Virtually every gap in training or understanding is created or reinforced by the literature they read.





### A funder's attempt to improve methodology: Minimal standards are not enough

### The case of the PCORI methods standards

(Patient-centered Outcomes Research Institute)





### **PCORI's Methodology Standards**

pcori

- Required by PCORI's authorizing law
- Developed by the Methodology Committee & adopted after public comment
- Represent <u>minimal</u> standards for design, conduct, analysis, and reporting of research.
- Used to:
  - ✓ Assess the rigor of applications
  - Monitor study conduct
  - ✓ Evaluate final research reports





# **PCORI** METHODOLOGY REPORT

January 2019

© 2019 Patient-Centered Outcomes Research Institute. All Rights Reserved.

The Methodology Standards were updated in February 2019 and are available at www.pcori.org/methodology-standards. An update to the Methodology Report will be posted later in 2019.



PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE

### 2019 PCORI Methodology Standards

#### 65 standards grouped in 16 topic areas

#### **Cross-Cutting Standards (5)**

- Formulating Research Questions
- Patient Centeredness
- Data Integrity & Rigorous Analyses
- Preventing/Handling Missing Data
- Heterogeneity of Treatment Effects

#### Design-Specific Standards (11)

- Data Registries
- Data Networks
- Causal Inference Methods
- Adaptive & Bayesian Trial Designs
- Studies of Medical Tests
- Systematic Reviews
- Research Designs Using Clusters (2016)
- Studies of Complex Interventions (2018)
- Qualitative Methods (2019)
- Mixed Methods Research (2019)
- IPD-MA (2019)





### Standards for Preventing and Handling Missing Data

- MD-1: Describe methods to prevent and monitor missing data.
- MD-2: Use valid statistical methods to deal with missing data that properly account for statistical uncertainty due to missingness. .....Estimates of treatment effects or measures of association should ....account for statistical uncertainty attributable to missing data. Methods used for imputing missing data should produce valid confidence intervals and permit unbiased inferences. ... Single imputation methods, such as last observation carried forward, baseline observation carried forward, and mean value imputation, are discouraged...
- MD-3: Record and report all reasons for dropout and missing data, and account for all patients in reports.
- MD-4: Examine sensitivity of inferences to missing data methods and assumptions, and incorporate into interpretation.





#### PCORI Methodology Standards Checklist

Follow the instructions provided below. Upload the completed template as an Excel file into PCORI Online. Detailed instructions are included in the Application Guidelines for this PCORI Funding Announcement (PFA). Refer to the PCORI Methodology Report for explanations about the matardards. Note that the Methodology Standards in red text indicate those that are newly adopted, as of February 26, 2019, by the Board of Governors.

In the checklist below, you will see a complete list of the PCORI Methodology Standards. In column D, using the drop-down menu options, indicate whether or not each methodology standard applies to your research. If the standard applies, in column E, provide the page number and section of your research plan where the text illustrates how you addressed the standard. Lastly, in column F, indicate whether your study may deviate from the standard and provide a rationale. Repeat the sequence for each standard. Note: Do not alter any formating of this template.

Application ID					
PI Name					
Application Title Standard Category	Abbrev.	Standard	Have you addressed how you plan to adhere to the standard in your application?	List page numbers	Notes
		Cross	Cutting Standards for F	COR	
	RQ-1	Identify gaps in evidence			
	RQ-2	Develop a formal study protocol			
Standards for	RQ-3	Identify specific populations and health decision(s) affected by the research			
Formulating Research Questions	RQ-4	Identify and assess participant subgroups			
	RQ-5	Select appropriate interventions and comparators			
	RQ-6	Measure outcomes that people representing the population of interest notice and care about			
	PC-1	Engage people representing the population of interest and other relevant stakeholders in ways that are appropriate and necessary in a given research context			
Standards Associated with Patient- Centeredness	PC-2	Identify, select, recruit, and retain study participants representative of the spectrum of the population of interest and ensure that data are collected thoroughly and systematically from all study participants			
	PC-3	Use patient-reported outcomes when patients or people at risk of a condition are the best source of information for outcomes of interest			
	PC-4	Support dissemination and implementation of study results			
	IR-1	A priori, specify plans for data analysis that correspond to major aims			
	IR-2	Assess data source adequacy			
	IR-3	Describe data linkage plans, if applicable			
	IR-4	Document validated scales and tests			
Standards for Data Integrity and Rigorous Analyses	IR-5	Provide sufficient information in reports to allow for assessments of the study's internal and external validity			
	IR-6	Masking should be used when feasible			
	IR-7	In the study protocol, specify a data management plan that addresses, at a minimum, the following elements: collecting data, organizing data, handing data, describing data, preserving data, and sharing data.			





	MD-1	Describe methods to prevent and monitor missing data			
Standards for Preventing and Handling Missing Data	MD-2	Use valid statistical methods to deal with missing data that properly account for statistical uncertainty due to missingness			
	MD-3	Record and report all reasons for dropout and missing data, and account for all patients in reports			
	MD-4	Examine sensitivity of inferences to missing data methods and assumptions, and incorporate into interpretation			
	HT-1	State the goals of HTE analyses, including hypotheses and the supporting evidence base			
Standards for Heterogeneity of Treatment Effect	HT-2	For all HTE analyses, provide an analysis plan, including the use of appropriate statistical methods			
(HTE)	HT-3	Report all prespecified HTE analyses and, at minimum, the number of post-hoc HTE analyses, including all subgroups and outcomes analyzed			
			ecific Study Desig	is and Methods	
	DR-1	Requirements for the design of			
Standards for	DR-2	registries Documentation and reporting requirements of registry materials, characteristics, and bias			
Data Registries	DR-3	Adapting established registries for PCOR			
	DR-4	Documentation requirements when using registry data			
Standards for Data Networks as Research-	DN-1	Requirements for the design and features of data networks			
Facilitating Structures	DN-2	Selection and use of data networks			
	CI-1	CI-I: Specify the causal model underlying the research question ***CROSS-CUTTING STANDARD***			
	CI-2	Define and appropriately characterize the analysis population used to generate effect estimates			
Causal Inference Standards	CI-3	Define with the appropriate precision the timing of the outcome assessment relative to the initiation and duration of exposure			
	CI-4	Measure potential confounders before start of exposure and report data on potential confounders with study results			
	CI-5	Report the assumptions underlying the construction of propensity scores and the comparability of the resulting groups in terms of the balance of covariates and overlap			
	CI-6	Assess the validity of the instrumental variable (i.e. how the assumptions are met) and report the balance of covariates in the groups created by the instrumental variable			







Standards for Adaptive and Bayesian Trial Designs	AT-1	Specily planned adaptations, decisional finesholds, and statistical properties of those adaptations
	AT-2	Specify the structure and analysis plan for Bayesian adaptive randomized clinical trial designs
	AT-3	Ensure that clinical trial inflatationshare is adequate to support planned adaptation(s) and independent interim analyses
	AT-4	When reporting Mappie randomized clinical trials, use the CONSORT satement, with modifications
	MT-1	Specify the clinical context and key elements of the medical test
Standards for Studies of Medical Tests	MT-2	Assess the effect of factors known to affect performance and outcomes
	MT-3	Focus studies of medicalitests on patient-contend extromme, using rightous study designs with a preference for randomized controllectifials
Standards for Systematic Reviews	SR-1	Adhers to National Academy of Medicine (NAM) standards for systematic reviews of comparative effectiveness research, as oppropriate
	RC-1	Specify whether the study objectives, the interventions, and the primary outcome pertain to the cluster level or the individual level
	RC-2	Justify the choice of cluster randomization
Standards on Research Designs Using Clusters	RC-3	Power and sample size estimates must use appropriate methods as account for the dependence of disservations within clusters and the degrees of freedom available at the cluster feed
	RC-4	Data analyses must account for the dependence of obsenations within clusters regardless of its magnitude
	RC-6	Stratified randomization should be used when feasible
	SCI-1	Fully describe the intervention and comparator and define their core functions
	SCI-2	Specify the hypothesized causal pathways and their theoretical basis.
Standards for Studies of Complex Interventions	SCI-3	Specify how adaptations to the form of the intervention and comparator will be allowed and recorded
	SCI-4	Plan and describe a process evaluation
	SCI-5	Select patient outcomes informed by the causal pathway
	QM-1	State the qualitative approach to research inquiry, design, and conduct
Standards for Qualitative Methods	QM-2	Select and justify appropriate qualitative methods sampling strategy
menous	QM-3	Link the qualitative data analysis, interpretations, and conclusions to the study question
	QM-4	Establish trustworthiness and credibility of qualitative research
	MM-1	Specify how mixed methods are integrated across design, data sources, and/or data collection phases
Standards for Mixed Methods Research	MM-2	Select and justify appropriate mixed methods sampling strategy
	MM-3	Integrate data analysis, data interpretation, and conclusions
Standards for Individual Panticipant-Level Data Meta- Analysis (PD-MA)	IPD-1	Specify the research question(a) that will be addressed through the PD-MA and describe the specific information it will provide that divergence the specific information it will provide that divergence the specific information it
	IPD-2	Describe the proposed governance structure for the IPD-MA in the protocol and study reports
	IPD-3	in or produced and study reports Use systematic, reproducible methods to identify studies for inclusion in the PD-DMA
	IPD-4	Specify the design and planned analyses of the IPDMA in a protocol, document any changes, and report significant anerdendress and registrations







#### METHODOLOGY STANDARDS

Please report how your project meets <u>PCORI's Methodology Standards</u> that apply to your ongoing research (enter N/A if appropriate). The following Standards should be addressed at the appropriate study phases (see table below):

Methodology Standards to address	Report how these Methodology Standards are being met
Standards for Formulating Research Questions	The trial design was developed using PRECIS-2 framework and adheres to PCORI methodology standards. Per RQ-1, the research question was determined based on identification of practice variation with clinicians equally committed to each intervention, and gap analyses from two recent systematic reviews from the investigative team and others establishing clinical equipoise between INTERVENTION X and INTERVENTION Y. A formal study protocol was developed stating research objectives, study design, exposures, analysis and outcomes and has been registered on clinicaltrials.gov per RQ-2. The primary objective of the trial is to compare the effectiveness of INTERVENTION X versus INTERVENTION Y
	among patients with CONDITION Z; which are in accordance to RQ-3 and RQ-6 Standards Effectiveness will be measured based on reduced duration of feeding tube dependency an outcome valued equally by patients, caregivers and clinicians (RQ-6). In addition, we have identified several participant subgroups for whom differences in treatment response or swallowing outcomes may exist, per PCORI Methodology Standard (RQ-4): namely, age at diagnosis, HPV status, prior surgery, radiation therapy dose, addition of chemotherapy and use of prophylactic feeding tube.
Standards Associated with Patient Centeredness	Through stakeholder engagement, we continue to give ongoing feedback to the Tria Executive Committee by engaging several groups of stakeholders partners (patients family caregivers, policy makers and payer representatives, as well as clinicians from multiple disciplines) at all phases of the study, from conception through dissemination Stakeholders engage in meaningful input and decision-making in collaborative settings as part of homogeneous stakeholder groups as well as a multi-disciplinary Stakeholder Advisory Board (PC-1). In Module 01, stakeholders informed the implementation of the criteria for 'trigger' in Arm 01 INTERVENTIN X patients. In Module 02, stakeholder reviewed and provided recommendations for secondary outcomes aligning with PCOR Methodology Standard (PC-3), some of which following review by the Trial executive Committee have now been incorporated in the last REB/IRB amendment. In year 04, stakeholders will also engage in review and interpretation of study finding: and together, we will design and execute the implementation and dissemination plan (PC 4).
Standards for Data Integrity & Rigorous Analyses	This is a patient-centered trial. All patients eligible for the trial will be approached by study coordinator for consent to capture a representative spectrum of the target population, in accordance with PCORI Methodology Standard PC-2. A quantitative data analysis plan have been determined a priori that correspond to majo aims (PCORI Methodology Standards IR-1). For Aim 1, an intention-to-treat (ITT) approach will be applied incorporating a gate-keeper method to control risk of Type I error in the setting of multiple comparisons. The initial analysis will compare the INTERVENTION X to the combined INTERVENTION Y groups in terms of the duration of outcome within the 12 month study period by means of a multiple linear regression model with covariate adjustment. If this test yields p < 0.05, the two INTERVENTION Y groups will be compared
	using the same linear analysis method. The meaningful variables proposed to include in the regression model are: age; HPV status; surgery (yes/no); chemotherapy (yes/no) radiation dose; and facility. The data management plan was developed in accordance with PCORI Methodology Standards for Data Integrity and Rigorous Analysis (Consortium Contractual Arrangement – ) (IR-7). Data sources include the electronic health record, imaging data (videofluoroscopy), and a mixture of clinician-graded and patient-reported outcome: reported using validated scales and tests (IR-4). Linkage of study, clinical, and imaging source data (IR-3) will be maintained in the secure central database via unique study identifiers. All source data will derive from individual level patient records maintained ir each participating site's health record or study forms although patient information will be







International Congress on<br/>Peer Review and Scientific PublicationEnhancing the quality and credibility of scienceSeptember 12-14, 2021 | Chicago, USA

Home | Program and Abstracts | Organizers and Advisory Board | Sponsors and Exhibitors | Invited Speakers | Previous C

#### Patient-Centered Outcomes Research Institute (PCORI) Methodology Standards to Improve the Design and Reporting of Research

Evan Mayo-Wilson,<sup>1</sup> Kelly Vander Ley,<sup>2</sup> Kay Dickersin,<sup>1</sup> Mark Helfand<sup>2</sup>

**Objective** The Patient-Centered Outcomes Research Institute (PCORI) began receiving funding applications in September 2011 and published Methodology Standards in November 2013 addressing issues related to research design and transparent reporting. PCORI requires that investigators of funded studies submit a draft final research report (DFRR) that is peer reviewed by an external team; after revision, in response to peer-review, the final report is published on the PCORI website. We sought to determine whether research described in DFRRs adheres to the PCORI standards.



### **Mayo-Wilson Results**

### > 0 of 31 final reports adhered to all the standards.

- Due to incomplete reporting and nonadherence with recommendations.
- (1) Most reports neither included nor cited a systematic review, and most did not include or cite a study protocol
- (4) Many reports did not use appropriate methods for handling missing data
- (5) Most reports examined heterogeneity with subgroup analyses, but few studies conducted confirmatory tests for heterogeneity.





### Implications

- Even a funder with substantial leverage and resources has difficulty changing dominant paradigms of practice, no less paradigms of reasoning.
- We are now conducting a portfolio review to see which manuscript problems are detectable or preventable in the initial stages of the proposed research.
- The difference between technical solutions (the standards) and true policy solutions (getting them used, no less understood) is enormous; the latter is more important and much harder.





#### natureresearch Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

#### Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

- n/a Confirmed
  - The <u>exact sample size</u> (*n*) for each experimental group/condition, given as a discrete number and unit of measurement
  - 🗌 🔀 An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
  - The statistical test(s) used AND whether they are one- or two-sided
  - Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistics including <u>central tendency</u> (e.g. means) or other basic estimates (e.g. regression coefficient) AND <u>variation</u> (e.g. standard deviation) or associated <u>estimates of uncertainty</u> (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. *F*, *t*, *r*) with confidence intervals, effect sizes, degrees of freedom and *P* value noted *Give P values as exact values whenever suitable*.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
- Clearly defined error bars
  - State explicitly what error bars represent (e.g. SD, SE, CI)

www.thelancet.com Vol 374 August 8, 2009

### The art of medicine

### Reality check for checklists

\*Charles L Bosk, Mary Dixon-Woods, Christine A Goeschel, Peter J Pronovost

[Peter Pronovost's commentary on the misinterpretation of his celebrated "checklist" that purportedly eliminated central line infections in Michigan hospitals.]

The study was widely reported in the popular media and elsewhere as a triumph of the "simple checklist" as a solution to patients' safety problems. Yet the widespread interest in this study is a dual-edged sword.

It was a great story...The problem is that the story may well have been oversimplified. The emphasis on checklists is a Hitchcockian "McGuffan", a distraction from the plot that diverts attention from how safer care is really achieved...widespread deployment of checklists without an appreciation of how or why they work is a potential threat to patients' safety and to high-quality care.







www.thelancet.com Vol 374 August 8, 2009

### **The art of medicine** Reality check for checklists

\*Charles L Bosk, Mary Dixon-Woods, Christine A Goeschel, Peter J Pronovost

The mistake of the "simple checklist" story is in the assumption that a technical solution (checklists) can solve an adaptive (sociocultural) problem...

Emphasising checklists as the explanatory mechanism for the reduction in catheter related infections obscures the complex labour necessary to create a collective local faith in checklists. How support was mobilised for coordinating work around infection control is the real story of the Keystone ICU project.





www.thelancet.com Vol 374 August 8, 2009

### **The art of medicine** Reality check for checklists

\*Charles L Bosk, Mary Dixon-Woods, Christine A Goeschel, Peter J Pronovost

Another important feature is the emphasis of the model on conferring legitimacy on the intervention. This was achieved by allowing teams to customise the implementation of evidence locally, and challenging assumptions about who has relevant knowledge, who counts as an expert, and who is able and ought to act to improve safety. **Indeed, it would be a mistake to say there was one "Keystone checklist": there was not a uniform instrument, but rather, more than 100 versions**. Each ICU, informed by evidence and a prototype, was encouraged to develop their own checklist to fit their unique barriers and culture. Taken together, what the Keystone programme did was change workers' motives for cooperating so that they internalised new norms.





18

### **The art of medicine** Reality check for checklists

When we begin to believe and act on the notion that safety is simple and inexpensive, that all it requires is a checklist, we abandon any serious attempt to achieve safer, higher quality care. Reporting the Keystone initiative as a success of checklists teaches the wrong lesson: namely, that reliable, safe care requires nothing more than insisting upon routine, standardised procedures.

The "simple checklist" stories in the press created excitement about progress in achieving patients' safety and reassurance for the public and policy makers, but the real story of Keystone is messier and more complex. Although we all hope for the simple solution that with ease and no additional expense makes a stay in the ICU safer, there is some danger in mistaking hope for reality. The answer to the question of what a simple checklist can achieve is: on its own, not much.







# Where do we go from here?

- Technical fixes alone will not work. Checklists/minimal reporting standards are *reminder* systems; they do not substitute for understanding how the plane flies.
- If the users don't have that understanding, enforcing de minimus reporting requirements can require de maximus effort with de minimus results.
- Pressure & legitimacy needs to be exerted at all levels, from funders, journals, regulators, professional societies, but change occurs at the ground level, and must include education + the means to operationalize it.
- Improving research practices must be driven by scientists reforming their own fields with the help of R&R experts, impelled by institutional leadership, manifest by structures & metrics.
- We need to partner with and learn from those who study institutional and disciplinary change, e.g. sociologists and organizational experts.



